Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 66.56B 58.3B 53.7B 49.84B 94.65B 6,349B 95.93B 643B 250B 3,117B 250B 244B 10,806B P/E 2026 *
16.9x
P/E 2027 * 13.6x
Enterprise Value 58.69B 51.4B 47.34B 43.94B 83.45B 5,598B 84.58B 567B 221B 2,748B 220B 216B 9,528B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.19x
Free-Float
72.33%
Yield 2026 *
0.6%
Yield 2027 * 0.68%
1 day-0.73%
1 week+2.77%
Current month+4.13%
1 month+6.21%
3 months-14.90%
6 months-16.38%
Current year-15.88%
1 week 622.29
Extreme 622.29
657.96
1 month 594.9
Extreme 594.9
657.96
Current year 591.52
Extreme 591.52
821.11
1 year 532.6
Extreme 532.6
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
05-01Sell

Director

-100 0.0001%
04-01Sell

Director

100 0.0001%
03-02Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%+2.77%+20.66%-7.88% 66.56B
-1.97%-3.45%+49.74%+221.13% 56.51B
-1.13%+40.50%+40.50%+40.50% 42.98B
+1.99%+8.15%-48.83%-54.69% 40.46B
-1.59%-1.86%+63.38%-25.40% 31.91B
+1.58%+16.93%+172.58%-31.10% 31.65B
-1.01%+0.91%+71.99%+84.06% 23.35B
+3.08%+20.43%+4.99%+186.85% 19.46B
+0.21%+3.76%+67.83%+133.69% 17.18B
+2.38%+9.96%+82.03%+365.79% 15.12B
Average +0.29%+9.25%+52.49%+91.30% 34.52B
Weighted average by Cap. -0.15%+7.82%+45.25%+67.01%

Financials

2026 *2027 *
Net sales 15.89B 13.92B 12.82B 11.9B 22.6B 1,516B 22.9B 153B 59.73B 744B 59.69B 58.38B 2,580B 17.58B 15.4B 14.18B 13.16B 24.99B 1,677B 25.33B 170B 66.06B 823B 66.02B 64.57B 2,854B
Net income 4.09B 3.58B 3.3B 3.06B 5.81B 390B 5.89B 39.48B 15.36B 191B 15.35B 15.02B 664B 5.13B 4.5B 4.14B 3.84B 7.3B 490B 7.4B 49.57B 19.29B 240B 19.28B 18.85B 833B
Net Debt -7.88B -6.9B -6.35B -5.9B -11.2B -751B -11.35B -76.05B -29.6B -369B -29.58B -28.93B -1,279B -10.53B -9.22B -8.49B -7.88B -14.97B -1,004B -15.17B -102B -39.56B -493B -39.53B -38.67B -1,709B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
06/07/26 $649.35 -0.75% 451,067
02/07/26 $654.27 +4.73% 1,071,604
01/07/26 $624.72 +0.19% 1,170,657
30/06/26 $623.54 -1.31% 820,925
29/06/26 $631.81 -0.17% 734,528
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
654.27USD
Average target price
826.52USD
Spread / Average Target
+26.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock